Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems

BMC Bioinformatics

Volumn 12, Issue , 2011, Pages

  Hess, Kenneth R ^a   Wei, Caimiao ^a   Qi, Yuan ^a   Iwamoto, Takayuki ^a   Symmans, W Fraser ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER DATA; CLINICAL CLASSIFICATION; EXPRESSION LEVELS; GENE EXPRESSION ANALYSIS; GENE EXPRESSION DATA; NUMBER OF SAMPLES; PREDICTION PROBLEM; PREDICTIVE TOOLS;

DISEASES; FORECASTING; MATHEMATICAL MODELS; PROBES;

GENE EXPRESSION;

ESTROGEN RECEPTOR;

ARTICLE; BIOLOGICAL MODEL; BREAST TUMOR; COMPUTER PROGRAM; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, GENETIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ESTROGEN; SOFTWARE;

EID: 82355160911     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-12-463     Document Type: Article

References (30)

1. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
2. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679.
3. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98(17):1183-1192. 10.1093/jnci/djj329, 16954471.
4. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006, 24(26):4236-4244. 10.1200/JCO.2006.05.6861, 16896004.
5. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006, 95(3):229-233. 10.1007/s10549-005-9009-7, 16322899.
6. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007, 104(32):13086-13091. 10.1073/pnas.0610292104, 1941805, 17666531.
7. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102(38):13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
8. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344(8):539-548. 10.1056/NEJM200102223440801, 11207349.
9. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010, 107(22):10208-10213. 10.1073/pnas.0907011107, 2890442, 20479250.
10. Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, Baggerly K, Rouzier R, Pusztai L. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2010, 16(2):711-718. 10.1158/1078-0432.CCR-09-2247, 2807997, 20068086.
11. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010, 16(21):5351-5361. 10.1158/1078-0432.CCR-10-1265, 20829329.
12. Baggerly KA, Coombes KR. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat 2009, 3(4):1309-1334.
13. Ioannidis JP, Allison DB, Ball CA, Coulibaly I, Cui X, Culhane AC, Falchi M, Furlanello C, Game L, Jurman G, et al. Repeatability of published microarray gene expression analyses. Nat Genet 2009, 41(2):149-155. 10.1038/ng.295, 19174838.
14. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98(4):262-272. 10.1093/jnci/djj052, 16478745.
15. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003, 9(7):2406-2415.
16. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001, 61(16):5979-5984.
17. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
18. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360(8):790-800. 10.1056/NEJMra0801289, 19228622.
19. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 2010, 12(1):R5. 10.1186/bcr2468, 2880423, 20064235.
20. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010, 28(8):827-838. 10.1038/nbt.1665, 20676074.
21. Dudoit S, Fridlyand J. Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 2002, 97:77-87. 22.
22. Strimmer K. A unified approach to false discovery rate estimation. BMC Bioinformatics 2008, 9:303. 10.1186/1471-2105-9-303, 2475539, 18613966.
23. Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, Dumur CI, Medeiros F, Anderson GG. Multicenter validation of a 1, 550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009, 27(15):2503-2508. 10.1200/JCO.2008.17.9762, 19332734.
24. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007, 99(2):147-157. 10.1093/jnci/djk018, 17227998.
25. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010, 11(4):358-365. 10.1016/S1470-2045(10)70018-8, 20189874.
26. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009, 11(2):R15. 10.1186/bcr2234, 2688939, 19272155.
27. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008, 68(13):5405-5413. 28, 10.1158/0008-5472.CAN-07-5206, 18593943.
28. Boulesteix AL, Strobl C, Augustin T, Daumer M. Evaluating microarray-based classifiers: an overview. Cancer Informatics 2008, 6:77-97. 2623308, 19259405.
29. Sontrop HMJ, Moerland PD, van den Ham R, Reinders MJT, Verhaegh WFJ. A comprehensive sensitivity analysis of microarray breast cancer classification under feature variability. BMC Bioinformatics 2009, 10:389. 10.1186/1471-2105-10-389, 2789744, 19941644.
30. Kim SY. Effects of sample size on robustness and prediction accuracy of a prognostic gene signature. BMC Bioinformatics 2009, 10:147. 10.1186/1471-2105-10-147, 2689196, 19445687.